Literature DB >> 22018284

MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.

Kohei Nakata1, Kenoki Ohuchida, Kazuhiro Mizumoto, Tadashi Kayashima, Naoki Ikenaga, Hiroshi Sakai, Cui Lin, Hayato Fujita, Takao Otsuka, Shinichi Aishima, Eishi Nagai, Yoshinao Oda, Masao Tanaka.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) have been gaining attention as new, key molecules that contribute to carcinogenesis. In pancreatic cancer, previous profiling analyses of miRNA expression have shown that several miRNAs are differently expressed in normal and cancerous tissues. Several pancreatic cancer-specific miRNAs differed, however, in each analysis.
METHODS: We investigated the miRNA expression profiles of the pancreatic cancer cell lines CAPAN-1 and CFPAC1 and an immortalized human normal pancreatic ductal epithelial cell line (HPDE) using a high-throughput, TaqMan, qRT-PCR array analysis. We also analyzed the expression levels of this miRNA in microdissected (n = 15) and formalin-fixed, paraffin-embedded (FFPE) (n = 115) samples from pancreatic cancers by quantitative RT-PCR. Finally, we investigated the effects of this miRNA on the invasiveness of pancreatic cancer cells.
RESULTS: Based on the microarray analysis, miR-372, miR-146a, miR-204, miR-10a, and miR-10b showed particularly large differences (>10-fold changes) between both pancreatic cell lines and HPDE cells. Thirteen of the 15 pancreatic cancer cell lines showed 2.1- to 36.4-fold (median, 15.3-fold) greater levels of miR-10b than HPDE cells. Microdissection analysis revealed that miR-10b exhibited greater expression levels in pancreatic cancer cells (n = 5) than in normal pancreatic ductal cells (n = 10) (P < .020). Analysis of FFPE samples showed that high miR-10b expression was associated with a lesser overall survival (P = .014). Furthermore, miR-10b correlated with the invasiveness of pancreatic cancer cells (P < .01).
CONCLUSION: miR-10b is overexpressed in pancreatic cancer and may be involved in the invasiveness in pancreatic cancer cells, thereby leading to a poor prognosis.
Copyright © 2011. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018284     DOI: 10.1016/j.surg.2011.06.017

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  77 in total

1.  High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells.

Authors:  Wei-Guang Li; Yao-Zong Yuan; Min-Min Qiao; Yong-Ping Zhang
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 2.  Targeting microRNAs in pancreatic cancer: microplayers in the big game.

Authors:  Sheema Khan; Deepak Kumar; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Res       Date:  2013-11-07       Impact factor: 12.701

Review 3.  MicroRNAs in pancreatic malignancy: progress and promises.

Authors:  Sanjeev K Srivastava; Sumit Arora; Seema Singh; Arun Bhardwaj; Courey Averett; Ajay P Singh
Journal:  Cancer Lett       Date:  2014-02-20       Impact factor: 8.679

Review 4.  MicroRNA in intervertebral disc degeneration.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2015-03-04       Impact factor: 6.831

5.  MicroRNAs as potential clinical biomarkers: emerging approaches for their detection.

Authors:  S K Srivastava; A Bhardwaj; S J Leavesley; W E Grizzle; S Singh; A P Singh
Journal:  Biotech Histochem       Date:  2013-01-07       Impact factor: 1.718

6.  Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Farah Logna; Bin Bao; Philip A Philip; Murray Korc; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

Review 7.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

8.  Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways.

Authors:  Jongchan Kim; Ashley N Siverly; Dahu Chen; Min Wang; Yuan Yuan; Yumeng Wang; Hyemin Lee; Jinsong Zhang; William J Muller; Han Liang; Boyi Gan; Xianbin Yang; Yutong Sun; M James You; Li Ma
Journal:  Cancer Res       Date:  2016-08-28       Impact factor: 12.701

9.  Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

10.  microRNA-10b is a prognostic biomarker for melanoma.

Authors:  Gerald Saldanha; Shona Elshaw; Parysatis Sachs; Hisham Alharbi; Prashant Shah; Ann Jothi; J Howard Pringle
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.